24/7 Market News Snapshot 06 May, 2025 – Pasithea Therapeutics Corp. Common Stock (NASDAQ:KTTA)

May 6, 2025

DENVER, Colo., 06 May, 2025 (www.247marketnews.com) – (NASDAQ:KTTA) are discussed in this article.
Pasithea Therapeutics Corp (KTTA) is currently witnessing a significant surge in stock value, with pre-market trading reflecting a remarkable rise of over 95.63%, reaching $2.778 from the previous close of $1.420. This bullish trend is supported by an impressive trading volume of 10.01 million shares, indicating considerable investor interest and enthusiasm surrounding the company’s innovative therapeutic efforts. Technical momentum indicators suggest a strong trajectory, with traders advised to monitor potential resistance levels closely as KTTA’s prospects continue to capture attention.

Adding to the excitement, Pasithea has recently announced promising interim results from its Phase 1 trial of PAS-004, a next-generation macrocyclic MEK inhibitor aimed at treating neurofibromatosis type 1 (NF1) and malignancies associated with the MAPK pathway. Data from cohorts 3 and 4A reveal substantial target engagement, highlighted by a peak pERK inhibition of 91% following an 8mg dosing regimen. These findings reinforce the drug’s favorable pharmacokinetic profile and its effectiveness in modulating the MAPK pathway in advanced cancer patients, with several subjects achieving stable disease and tumor reductions.

In particular, one participant in cohort 4A, who had stage 4 pancreatic cancer with a KRAS G12R mutation, demonstrated a tumor volume decrease of 9.8% over a five-month treatment span, maintaining participation in the study despite previous therapeutic failures. Dr. Tiago Reis Marques, Pasithea’s CEO, expressed optimism regarding the significant pERK reductions and the favorable safety profile of PAS-004, noting the absence of severe adverse effects. The ongoing, multi-center, open-label trial aims to further investigate the safety, tolerability, and preliminary efficacy of PAS-004 in advanced solid tumors with documented mutations, with additional updates expected in the forthcoming months, signifying a vital step in advancing treatment options within the MAPK pathway-driven cancer landscape.

Related news for (KTTA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.